drugset / Trial / NCT05022732
Polyglucosamine L112 in Overweight and Obese Subjects
RandomizedParallel-groupDouble-blindTreatment
Summary
This research proposes as its main purpose to evaluate the effectiveness of the intake of Polyglucosamine at a dose of 3 g / day on weight loss in a group of subjects suffering from overweight and mild obesity (BMI between 25 and 32 kg / m2). and with weight\> 75 kg
Timeline
- Start
- 2020-05-05
- Primary completion
- 2020-08-05
- Completion
- 2021-08-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Polyglucosamine L112 | Unknown | 3 g | — |